US Edition
Elixir Medical reports sustained durability with bioadaptor
Summary by Drug Delivery Business
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Elixir Medical reports sustained durability with bioadaptor
The DynamX [Image courtesy of Elixir Medical]Elixir Medical announced three-year results from a large randomized controlled trial of its DynamX coronary bioadaptor system. The 445-patient BIOADAPTOR trial compares DynamX to the standard of care Medtronic Resolute Onyx drug-eluting stent (DES). It took place across 34 centers in Japan, Europe and New Zealand. Data — shared this week at EuroPCR 2025 in Paris — adds to positive outcomes reported la…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
